Prostate cancer is the most common cancer, other than skin cancers, in American men. The American Cancer Society estimates that during 2008 about 186,320 new cases of prostate cancer will be diagnosed in the United States. About 1 man in 6 will be diagnosed with prostate cancer during his lifetime, but only 1 man in 35 will die of it. More than 2 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.

Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. The American Cancer Society estimates that 28,660 men in the United States will die of prostate cancer in 2008. Prostate cancer accounts for about 10% of cancer-related deaths in men.

The 5-year survival rate refers to the percentage of patients who live at least 5 years after their cancer is diagnosed. These rates are used to create a standard way of discussing prognosis (outlook). Of course, many of these patients live much longer than 5 years after diagnosis. Five-year survival rates are based on patients diagnosed and first treated more than 5 years ago. Improvements in treatment since then may result in a better outlook for recently diagnosed patients. Five-year relative survival rates compare the observed survival with that expected for people without the cancer. That means that relative survival only talks about deaths from the cancer in question. This is a more accurate way to describe the outlook for patients with a certain cancer.

According to the most recent data, for all men with prostate cancer, the relative 5-year survival rate is 100% and the relative 10-year survival rate is 92%. The 15-year relative survival rate is 70%. Keep in mind that 5-year survival rates are based on patients diagnosed and first treated more than 5 years ago, and 10-year survival rates are based on patients diagnosed more than 10 years ago. Modern methods of detection and treatment mean that many prostate cancers are now found earlier and can be treated more effectively. If you are diagnosed this year, your outlook is likely to be better than the numbers reported above.